257 related articles for article (PubMed ID: 9162907)
1. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
Moka D; Voth E; Schicha H
Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
[TBL] [Abstract][Full Text] [Related]
2. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
3. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
5. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
Eschmann SM; Thelen MH; Dittmann H; Bares R
Exp Clin Endocrinol Diabetes; 2006 May; 114(5):222-6. PubMed ID: 16804795
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
7. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy and thyrostatic drugs and iodine.
Moka D; Dietlein M; Schicha H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
[TBL] [Abstract][Full Text] [Related]
11. Graves' disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication?
Kobe C; Weber I; Eschner W; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(4):153-6. PubMed ID: 18690374
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism.
Chen DY; Jing J; Schneider PF; Chen TH
Nucl Med Commun; 2009 Feb; 30(2):160-8. PubMed ID: 19194213
[TBL] [Abstract][Full Text] [Related]
13. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
[TBL] [Abstract][Full Text] [Related]
14. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of diffuse hyperthyroid goiter with radioiodine: influence of propylthiouracil pretreatment].
Véliz J; Pineda G; Arancibia P; Wohllk N
Rev Med Chil; 2000 Jun; 128(6):609-12. PubMed ID: 11016059
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
17. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
Baczyk M; Junik R; Ziemnicka K; Sowiński J
Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
[TBL] [Abstract][Full Text] [Related]
18. The effect of carbimazole following radioiodine therapy on radiation dose to the thyroid.
Gimlette TM; Kocak R; Herbert RG; Squire CR
Nuklearmedizin; 1981 Apr; 20(2):72-5. PubMed ID: 6165965
[TBL] [Abstract][Full Text] [Related]
19. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
20. Antithyroid drug regimens before and after 131I-therapy for hyperthyroidism: evidence-based?
Mijnhout GS; Franken AA
Neth J Med; 2008 Jun; 66(6):238-41. PubMed ID: 18689906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]